New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS Additional poster ...

(RTTNews) - Myelodysplastic syndrome, which refers to a group of blood disorders, affects an estimated 60,000 people in the U.S. The abnormal or malignant precursor cells in the bone marrow ...

Please provide your email address to receive an email when new articles are posted on . Imetelstat conferred a “highly statistically significant and clinically meaningful benefit” vs. placebo in ...

Imetelstat improves eight- and 24-week transfusion independence in patients with low-risk myelodysplastic syndrome, according to topline study results. The phase 3 IMerge trial met its main goal, ...

The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, ...

With 99% of patients experiencing an adverse event, the FDA is skeptical that the risks associated with Geron’s myelodysplastic syndromes (MDS) medicine imetelstat outweigh the potential benefit of ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial. Patients with ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the ...

Geron Corporation has submitted its New Drug Application (NDA) to the FDA for its lead candidate, imetelstat, for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic ...

MENLO PARK, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to ...

Shares of Geron CorporationGERN increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate. So far this year, Geron's ...